Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03966287
Other study ID # 02202
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 3, 2019
Est. completion date March 31, 2020

Study information

Verified date November 2020
Source University Medical Center Goettingen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to qualitatively and quantitively evaluate pain in patients suffering from CMT with 3 standardized questionnaires (SF-36, NPSI-G, PAIN DETECT) as well as its impact on the quality of life.


Description:

Hereditary neuropathies are a group of clinically and genetically heterogeneous diseases of the peripheral nervous system. Charcot-Marie-Tooth disease (CMT), also known as hereditary motor and sensory neuropathy (HMSN), is the most common form of hereditary neuropathy with a prevalence of approximately 1 in 2,500 and with approximately 30,000 affected persons in Germany. There is no therapy known so far. In addition to the characteristic symptoms of a distal to proximal progressive symmetric muscular atrophy, especially of the lower extremities, there is a weakening of the muscles of the lower legs and feet, with emphasis on the "small" foot muscles and the peroneal muscle group, which clinically manifests as a so-called "stepper gait". It is also known that many CMT patients additionally suffer from pain, but more detailed studies on pain quality and quantity and their impact on patients' quality of life have not yet been systematically performed. These parameters will be investigated in this study, supported by the company Grünenthal, in the form of a questionnaire survey with validated questionnaires on pain and quality of life for at least 200 CMT patients. A representative result could lead to further investigations of pain in CMT patients and ultimately to the development of an adequate pain therapy. Recruitment of patients will occur mainly through a call of the Germany-wide CMT registry, which is part of the national research network CMT-NET (coordinator: Prof. Michael Sereda). Interested patients are invited to contact the study team at the UMG. The patients will be informed about the study and if further interested 4 questionnaires (1 regarding the personal history as well as 3 standardized questionnaires from literature regarding quality of life and pain (SF-36, NPSI-G, PAIN DETECT) will be sent to the patients together with obligatory study documents and a pre-franked return envelope. A personal visit at the UMG is not planned, so that the patients don´t have any expenses. The data are pseudonymized at the UMG and transferred to a database and finally statistically evaluated by Gruenenthal.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date March 31, 2020
Est. primary completion date January 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of CMT - Genetic confirmation of CMT diagnosis - Age between 18 and 65 years - Signed consent form Exclusion Criteria: - Other relevant neurological or psychiatric diseases, acute or past - Serious internal medical illness - Drug and / or alcohol dependence - Participation in another clinical trial within 4 weeks prior to enrollment

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany University Medical Centre Goettigen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Goettingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary SF-36 Questionnaire Questionnaire to evaluate health status 1 year
Primary NPSI-G Questionnaire Questionnaire to discriminate neuropathic and non-neuropathic pain 1 day
Primary PAIN DETECT Questionnaire Questionnaire for the diagnosis of neuropathic pain (intensity, pattern, quality) 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05361031 - The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) Phase 1/Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project